MedTrace Logo

Efficacy of Fusidic Acid 1% in the Treatment of Bacterial Conjunctivitis

NCT06911424 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2026-03-17

No results posted yet for this study

Summary

The purpose of this clinical trial is to demonstrate the superiority of fusidic acid 1% over placebo in adults and children with confirmed bacterial conjunctivitis and to further establish the safety profile of fusidic acid 1% for topical ocular administration.

Conditions

  • Bacterial Conjunctivitis

Interventions

DRUG

Fusidic Acid 1%

Fusidic acid 1%

DRUG

Placebo

Placebo ophthalmic solution

Sponsors & Collaborators

  • Baxis Pharmaceuticals, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-21
Primary Completion
2026-03-16
Completion
2026-03-23
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06911424 on ClinicalTrials.gov